Surveillance of Barrett's Esophagus Patients in an Expert Center is Associated With Low Disease‐Specific Mortality
United European Gastroenterology Journal · 2025
DOI: 10.1002/ueg2.12759 ↗Kurz gefasst
Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2025. Verfasst von Judith Honing und 11 weiteren Autor:innen. Beteiligte Einrichtung: Early Cancer Institute, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Barrett Esophagus, Esophageal Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Cambridge Biomedical Research Center, Cancer Research UK, NIHR Cambridge Biomedical Research Centre.
Abstract (Originalsprache)
Introduction
Specialist guidelines recommend endoscopic surveillance for Barrett's esophagus to reduce mortality related to esophageal adenocarcinoma, but the setting for optimal Barrett's esophagus monitoring is unclear. We assessed progression rate and disease‐specific mortality in a large cohort of patients followed up at a single Barrett's esophagus expert center.
Methods
For this prospective longitudinal single center cohort study, we recruited patients with a previous diagnosis of Barrett's esophagus between 2004 and 2022. Endoscopists were trained in Barrett's esophagus surveillance standards and image‐enhanced techniques, and biopsies were reviewed by expert pathologists. Exclusion criteria were a single surveillance endoscopy, high‐grade dysplasia, or esophageal adenocarcinoma at or within 12 months from index endoscopy and patients with < 12 months follow‐up. The primary outcome was the neoplastic progression rate of Barrett's esophagus with intestinal metaplasia to high‐grade dysplasia/esophageal adenocarcinoma. Secondary outcomes included cancer stage and disease‐specific mortality, risk factors for progression and progression rate in patients with Barrett's esophagus with only gastric metaplasia or irregular z‐line and intestinal metaplasia (IZL‐IM).
Results
A total of 1932 patients were recruited, of which 969 were included in the primary analysis with a median follow‐up of 5.8 years. Of these, 109 developed high‐grade dysplasia or esophageal adenocarcinoma with a progression rate of 1.63%/year. Overall, 48 patients received an esophageal adenocarcinoma diagnosis, of which 89,5% (43/48) had stage 1, and 0.3% patients (3/969) had disease‐specific mortality. Multivariate analysis showed that age, alcohol consumption, esophagitis, Barrett's esophagus length, hiatus hernia length, low‐grade dysplasia and neutrophil/lymphocyte ratio were risk factors for progression. The rate of progression in patients with Barrett's esophagus—gastric metaplasia or IZL‐IM was 0.06%/year.
Conclusions
Endoscopic surveillance in an expert Barrett's esophagus center leads to a high neoplastic progression rate, and a low rate of disease‐specific mortality. Further research to correlate disease‐specific mortality and cancer stage with dysplasia detection rate is warranted to develop diagnostic quality indicators specific for Barrett's esophagus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Early Cancer Institute, University of Cambridge, Cambridge, UK.
- Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands.
- Department of Gastroenterology, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.
- School of Clinical Medicine, University of Cambridge, Cambridge, UK.
- Cambridge Oesophagogastric Centre, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.
ORCID-Profile: Victor Yan Zhe Lu, Vlasios Gourgiotis
Förderung
- NIHR Cambridge Biomedical Research Center
- Cancer Research UK
- NIHR Cambridge Biomedical Research Centre
Zitieren
APA
Honing, J., Tan, W. K., Lu, V. Y. Z., Gourgiotis, V., Gianfrancesco, I. M., Schumacher, A. A., Vishwanathan, S., Cheah, C., Modolell, I., Sujendran, V., Fitzgerald, R. C., & di Pietro, M. (2025). Surveillance of Barrett's Esophagus Patients in an Expert Center is Associated With Low Disease‐Specific Mortality. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12759
Vancouver
Honing J, Tan WK, Lu VYZ, Gourgiotis V, Gianfrancesco IM, Schumacher AA, et al. Surveillance of Barrett's Esophagus Patients in an Expert Center is Associated With Low Disease‐Specific Mortality. United European Gastroenterology Journal. 2025. doi:10.1002/ueg2.12759
BibTeX
@article{Honing2025,
author = {Honing, Judith and Tan, W Keith and Lu, Victor Yan Zhe and Gourgiotis, Vlasios and Gianfrancesco, Isaac M and Schumacher, Alina A and Vishwanathan, Shriya and Cheah, Calvin and Modolell, Ines and Sujendran, Vijay and Fitzgerald, Rebecca C and di Pietro, Massimiliano},
title = {Surveillance of Barrett's Esophagus Patients in an Expert Center is Associated With Low Disease‐Specific Mortality},
journal = {United European Gastroenterology Journal},
year = {2025},
doi = {10.1002/ueg2.12759}
}
EUVIMED